Search filters

Filters
Clear All

Phase

  • 2
  • 6
  • 1
  • 5
  • 7
  • 23
  • 10
  • 23

Found 23 Pancreatitis trials

A listing of Pancreatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
18 years - 80 years
All genders
Phase 2
Interventional
The research study is being conducted to see how safe and effective an investigational drug called evinacumab is in people who have severe hypertriglyceridemia (elevated levels of fat in the blood).
 A Phase 2  Randomized  Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
99 years or below
All genders
Phase 2
A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …
 Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism
1 years - 99 years
All genders
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
 UPCC 35217: A Phase 1B/2  Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
99 years or below
All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
 Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer
99 years or below
All genders
Phase 1
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …
 A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
18 years - 99 years
All genders
Phase 1
Interventional
A study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.
 Precision Promise Platform Trial for Metastatic Pancreatic Cancer
99 years or below
All genders
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find effective therapies for pancreatic cancer. The platform will rapidly and efficiently test multiple novel drugs and combinations compared to standard of care therapy …
 Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma
18 years - 99 years
All genders
Phase 1
Interventional
The purpose of this research study is to evaluate the safety, tolerability and efficacy of AVB-S6-500 combined with chemotherapies called nab-paclitaxel and gemcitabine in subjects with pancreatic cancer who have not received treatment previously.
 Determination of B-cell responsiveness to the incretin hormones GLP-1 and GIP in Cystic Fibrosis (PRIME)
18 years - 99 years
All genders
The mechanisms underlying cystic fibrosis related diabetes (CFRD) pathophysiology must be better defined if care for people with CFRD is to be optimized or if development of CFRD is to be interrupted. Detailed studies of insulin secretion in CF are required to achieve this goal since 1) subtle insulin secretion …
18 years - 50 years
All genders
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …
1 - 10 of 23